Taysha Gene Therapies Inc - TSHA Amount of Long-Term Liabilities

Graphic logo of Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies is developing innovative CNS treatments, leveraging partnerships with industry behemoths such as Astellas to accelerate commercialization. High business margins are driven by unique gene delivery methods, while output stability is guaranteed by calibrated precision dosing capacities. The price action on this chart, reflecting long-term debt levels at 0.06, verifies the company's fundamental resilience.

TSHA Taysha: Company Long-Term Liabilities in the range 07/04/2022 - 11/01/2026

Taysha (TSHA) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price tayshagtx.com|TSHA - Consensus Target
- issuer market value details:
Market Value Taysha Gene Therapies|TSHA - Enterprise Value
- issuer book value statistics:
Book Value per Share Taysha Gene Therapies|TSHA - Company Net Assets|Market-to-Book Ratio tayshagtx.com|TSHA - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Taysha Gene Therapies|TSHA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Taysha Corp|TSHA - Company Aggregate Debts|Debts to Book Capitalization Taysha Gene Therapies|TSHA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Taysha Gene Therapies|Critical Liquidity tayshagtx.com
- business earnings and investment ratios data:
TSHA - Net Profit
Summary company analytics:TSHA (tayshagtx.com)
Signature product of Taysha Corp

The market values Taysha Gene Therapies (TSHA) as an "asset-light" biotech structure that minimizes capital expenditures by fully outsourcing its DNA therapy clinical trials. Monitoring the organization's long-term financial debt allows for the measurement of obligations with maturities exceeding one year, determining the balance between default risk and the efficiency of credit leverage for scaling the business, which confirms the issuer's overall financial stability.

Competitor analysis for Taysha Gene Therapies

Company Long-Term Debts Tempus Labs TEM|QGEN: Company Long-Term Liabilities|Ionis Pharmaceuticals, Inc. - Amount of Long-Term Liabilities|RGEN: Company Long-Term Debts|Avidity Corp (RNA) - Company Long-Term Debts|Company Long-Term Liabilities CRSP|Long-Term Debt genedx.com WGS|Company Long-Term Debt Ultragenyx (RARE)|Long-Term Debt Volume Beam Therapeutics Inc|Company Long-Term Debts SRPT (Sarepta Therapeutics Inc)|Company Long-Term Loans and Borrowings TWST|10x Genomics, Inc. - Company Long-Term Debts|NTLA - Company Long-Term Debts|STOK (Stoke Therapeutics, Inc.) - Company Long-Term Liabilities|BioLife Solutions Inc - Company Long-Term Loans and Borrowings|WVE (Wave Life Sciences Corp) - Company Long-Term Debts|MAZE - Long-Term Indebtedness|Company Long-Term Debts SION|PRME - Long-Term Debt|Company Long-Term Debt uniQure QURE|MGTX: Company Long-Term Indebtedness|Regenxbio - Company Long-Term Debts|Long-Term Debt Solid Corp|OCGN (Ocugen, Inc.) - Company Long-Term Liabilities|pacb.com - Company Long-Term Loans and Borrowings|Company Long-Term Liabilities BNTC|DSGN (Design Therapeutics Inc) - Amount of Long-Term Liabilities|Company Long-Term Debts RCKT|FDMT (4D Molecular Corp) - Company Long-Term Loans and Borrowings|Company Long-Term Debts LXEO (Lexeo Therapeutics, Inc.)|Korro Bio Inc. (KRRO) - Long-Term Debt|EDIT - Company Long-Term Debt|Company Long-Term Loans and Borrowings SLN (Silence Therapeutics PLC)|PRQR: Company Long-Term Debts|Codexis (CDXS) - Company Long-Term Debts|Company Long-Term Debt Sangamo Therapeutics|Nautilus Biotechnology Inc - Long-Term Liabilities|Company Long-Term Debts MGX|Long-Term Debt Volume Precision BioSciences Inc.|Company Long-Term Debts GBIO (Generation Bio)|Boundless Bio Inc (BOLD) - Long-Term Debt|XCUR - Company Long-Term Debt|Long-Term Debt Volume Imunon, Inc. IMNN|PHIO (phiopharma.com) - Company Long-Term Liabilities|MBIO: Amount of Long-Term Liabilities|Company Long-Term Debt TransCode Therapeutics Inc.|Bionano (BNGO) - Long-Term Debt Volume|Company Long-Term Debts APDN|BLUE (bluebirdbio.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts IPA (ImmunoPrecise Antibodies Ltd.)|Company Long-Term Debts Omega Therapeutics Inc OMGA|Singular Genomics Systems Inc - Company Long-Term Debts|RGLS (Regulus) - Company Long-Term Indebtedness|Syros Pharmaceuticals (SYRS) - Company Long-Term Debt|Company Long-Term Indebtedness TBIO|TCON (TRACON Pharmaceuticals, Inc.) - Company Long-Term Debts|Company Long-Term Debts Unity Biotechnology Inc.